Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis

MA Bethel, RA Patel, P Merrill… - The lancet Diabetes & …, 2018 - thelancet.com
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists are effective
glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular …

[HTML][HTML] 10-year follow-up of intensive glucose control in type 2 diabetes

RR Holman, SK Paul, MA Bethel… - New England journal …, 2008 - Mass Medical Soc
Background During the United Kingdom Prospective Diabetes Study (UKPDS), patients with
type 2 diabetes mellitus who received intensive glucose therapy had a lower risk of …

[HTML][HTML] Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

JB Green, MA Bethel, PW Armstrong… - … England Journal of …, 2015 - Mass Medical Soc
Background Data are lacking on the long-term effect on cardiovascular events of adding
sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes …

[HTML][HTML] Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

RR Holman, MA Bethel, RJ Mentz… - … England Journal of …, 2017 - Mass Medical Soc
Background The cardiovascular effects of adding once-weekly treatment with exenatide to
usual care in patients with type 2 diabetes are unknown. Methods We randomly assigned …

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo …

AF Hernandez, JB Green, S Janmohamed… - The Lancet, 2018 - thelancet.com
Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …

HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression

MA Bethel, R Diaz, N Castellana, I Bhattacharya… - Diabetes …, 2021 - Am Diabetes Assoc
BACKGROUND Long-term glycemic control reduces retinopathy risk, but transient
worsening can occur with glucose control intensification. Glucagon-like peptide 1 receptor …

[HTML][HTML] Long-term follow-up after tight control of blood pressure in type 2 diabetes

RR Holman, SK Paul, MA Bethel… - … England Journal of …, 2008 - Mass Medical Soc
Background Post-trial monitoring of patients in the United Kingdom Prospective Diabetes
Study (UKPDS) examined whether risk reductions for microvascular and macrovascular …

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double …

RR Holman, RL Coleman, JCN Chan… - The lancet Diabetes & …, 2017 - thelancet.com
Background The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes
in patients with coronary heart disease and impaired glucose tolerance is unknown. We …

Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis

T Yates, SM Haffner, PJ Schulte, L Thomas… - The Lancet, 2014 - thelancet.com
Background The extent to which change in physical activity can modify the risk of
cardiovascular disease in individuals at high cardiovascular risk is uncertain. We …

Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial

DK McGuire, F Van de Werf, PW Armstrong… - JAMA …, 2016 - jamanetwork.com
Importance Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor
(DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The …